A detailed history of First Capital Advisors Group, Llc. transactions in Exelixis, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 97 shares of EXEL stock, worth $3,229. This represents 0.0% of its overall portfolio holdings.

Number of Shares
97
Holding current value
$3,229
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 15, 2023

BUY
$18.17 - $20.48 $1,762 - $1,986
97 New
97 $1,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track First Capital Advisors Group, Llc. Portfolio

Follow First Capital Advisors Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Capital Advisors Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on First Capital Advisors Group, Llc. with notifications on news.